Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas.
introduction
Osteosarcomas account for 40%-60% of primary bone neoplasms. Mandibular osteosarcomas (MOS) mostly affect young adults, on average two decades later than their long bone counterparts [1] [2] [3] [4] [5] [6] [7] . MOS are often analyzed with osteosarcomas of other sites despite seemingly different outcomes [1] [2] [3] [8] [9] [10] [11] [12] [13] [14] [15] and prognosis [7] [8] . Head and neck osteosarcomas have a presumably lower metastatic potential [16] . Indeed, given the possibilities of mandibular reconstruction, MOS are more prone to wide surgical excision with clear margins than other head and neck sites. Surgery is the mainstay of treatment, and margins are the most important factor for local control (LC) and survival. Data on histological response to chemotherapy, on the role of adjuvant radiotherapy [17] on LC in patients with positive margins and of neoadjuvant chemotherapy to prevent metastasis are rare in such localizations. Overall, the optimal management of highgrade MOS and other types of MOS remains to be defined. The aims of this study were to determine the role of surgery, chemotherapy, adjuvant radiotherapy depending on MOS histologies and grades and to identify prognostic factors.
patients and methods
In this retrospective study, data from 111 patients with MOS treated between 1973 and 2010 were collected in institutions of the Groupe Sarcomes Francais-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO) the Rare Cancer Network (RCN), the Groupe d'Etude des Tumeurs de la Tête et du Cou (GETTEC)/ Reseau d'Expertise Français des Cancers ORL Rares (REFCOR), and the Société Française des Cancers et Leucémies de l'Enfant et de l'Adolescent (SFCE). Inclusion criteria were confirmed pathological diagnosis, primary MOS (i.e. any primary mandibular location of an osteosarcoma, radiation-induced cases included but metastases from other cancers to the jaw excluded), nonmetastatic disease and a minimum of 6 months of follow-up after treatment. Institutional Review-Board approval for data collection on www.easy-crf.com/osteosarcoma was obtained. All the medical records were reviewed by the physician in charge for age, gender, medical history including a history of irradiation and genetic disease, physical examination, clinical symptoms, imaging, pathological diagnosis, stage according to Enneking and MSKCC classifications, size, treatment modalities, histological response to chemotherapy and outcomes. Biopsy and complete operative reports were collected. Early and late treatment toxic effects were evaluated according to the Common Terminology Criteria for Adverse Events (CTCAE) V3.0. Centralized histological review (AB) and centralized review of operative reports were carried out (TS, MJ). Histological subtypes were further divided into conventional [osteoblastic, chondroblastic, fibroblastic or conventional not otherwise specified (NOS)] or other types [5, 11-13, 15, 18-24] . Grading was determined independently from histological subtype [15, 22] . The Broder's and WHO 2002 grading systems low grade ( paraosteal or central) (Table 1) , intermediate ( periosteal), high grade (conventional, telangiectasic, and small cell) [22, [25] [26] were compared. Response to chemotherapy was evaluated using the Rosen's criteria to assess the percentage of necrotic tumor cells in the operative specimen following neoadjuvant chemotherapy. Nodal stage was dichotomized into negative or positive. Age, histological subtype, tumor size, quality of surgical margins, use of radiotherapy and chemotherapy were analyzed as potential prognostic factors for LC and survival.
Statistical methods
A casewise deletion method was used for missing data. Overall survival was calculated from the date of diagnosis to the date of 
treatment
Patients were treated according to each hospital's local policy with various modalities of treatment including chemotherapy, RT, surgical resection or a combination of these ( Figure 1 ). Data regarding neoadjuvant chemotherapy were available in 87 patients. Protocols included cisplatin, anthracycline, methotrexate, ifosfamide, etoposide and other drugs with various combinations. Among them it was carried out in 81 patients (93.1%) of cases and consisted of API/AI (adriamycin, cisplatin and ifosfamide), IVP (ifosfamide and etoposide), high-dose methotrexate (MTX)-based associations, other combinations or unspecified regimens in 46.8%, 3.7%, 9.2%, 12.8% and 1.9%, respectively. Using Rosen's criteria, favorable histological response was noted in 19 patients (27%). Forty-two patients (44%) of patients had both pre-and postoperative chemotherapy, of which, type depended on the response to neoadjuvant chemotherapy. Postoperative chemotherapy was carried out in 58 patients (54.7%) of patients with API/AI in 48.3%, IVP in 29.3%, MTX in 10.3% and other combinations in 12.1%.
One hundred five patients (94.5%) underwent surgery. Six patients (5.5%) were not operated on due to initially unresectable disease that progressed under noeadjuvant chemotherapy. Fifteen patients had a neck dissection. Five patients had metastatic nodes (5%). Sixty-eight patients had immediate reconstruction with free flap among 82 patients undergoing reconstruction. Twenty-two, 34 and 2 patients had clear margins over 2 cm, between 0.5 and 2 cm or without other specification, respectively. Thirty-four patients had R1 disease (margins < 0.5 cm) and one patient had involved margins. Equivocal data on histological reports, unavailable for review, were considered as missing values.
Postoperative radiation therapy was carried out in 25 patients (23.8%) including13 of those with incomplete margins (37.1%) and 9 of those with complete resection (16.7%) (P = 0.029). Fourteen patients had a dose ≥55 Gy. Patients with incomplete margins were more likely to receive ≥55 Gy (P = 0.002).
outcomes
With a median follow-up of 59.6 months (range 3-432 months), crude median LC, nodal control, metastasis-free survival and DFS and overall survival were 30.6 months (range 1-260), 49.1 months (range 2-432), 36.6 months (range 2-432) and 29 months (range 1-260), respectively ( Figure 2A ). The mean time from local failure to metastases was 7.3 months (range 134; 418). Median survival for nonoperated patients was 6 months (0-13) versus 260 months with surgery (0-546) (P < 0.0001). Five-year LC, regional control, metastasis-free survival, DFS and survival were 64.6% (± 5.3), 96.8% (± 1.9), 68.9% (± 5.3), 53.2% (± 5.3) and 69.2% (± 4.9), respectively ( Figure 2A ). At the time of analysis, the rates of patients alive without disease, alive with disease, dead without disease and dead with disease were 52.3%, 12.8%, 6.4% and 28.4%, respectively.
Of patients experiencing local failure, 57.6% had died at last follow-up, which compares with only 17.6% in patients without local relapse (P < 0.0001). Similarly, of patients experiencing metastatic failure, 60.0% had died at last followup, which compares with only 22.7% in patients without metastatic relapse (P < 0.0001).
prognostic factors
Age, size, histology, grade, the presence of lymphadenopathies, surgery significantly influenced survival on UVA (Table 2) . Surgery and age remained significant prognostic factors on MVA with patients <35 years having better survival while those <18 years had similar survival as those ≥18 years. There was a trend for better survival in patients without history of cancer.
Neoadjuvant chemotherapy increased DFS (P = 0.01) but not survival despite a clear trend for better survival in high-grade MOS. Intermediate-grade MOS behaved like high-grade tumors rather than low-grade tumors ( Figure 2B ). In UVA, DFS was worse without neoadjuvant chemotherapy (HR 2.87; 95% CI 1.10-7.51; P = 0.025) and without surgery (P = 0.011) or clear margins (P = 0.012) and worse without clear margins in MVA (HR 0.41; 95% CI 0.19-0.88; P = 0.022). Analyses restricted to the group of operated high-intermediate grade tumors revealed that histological subtype (conventional NOS group did worse), neoadjuvant chemotherapy and margins were significantly associated with DFS on UVA, and only histology and margins remained significant on MVA (Table 3) .
Sixty-three patients had clear margins (67%) following neoadjuvant chemotherapy, whereas five (40%) have clear original articles Annals of Oncology margins in the group of patients undergoing upfront surgery. Pathological response to preoperative chemotherapy did not come up as a prognostic factor. Clear margins were observed in 80% of patients with favorable histologic response versus 61% of patients with >10% residual viable tumor cells. Moreover, clear margins and incomplete margins were associated with 70.2% and 38.5% local relapse free rates, respectively (P = 0.006).
Thirty patients developed distant metastases (28.6%). Metastatic-free survival was associated with age, neoadjuvant chemotherapy, margins and local relapse ( Table 3 ). The metastatic rates were improved by neoadjuvant chemotherapy but did not differ significantly by the type of neoadjuvant and postoperative chemotherapy.
Clear margins were strongly associated with better LC (Table 3 ). The LC rates were higher in the API-AI-based postoperative chemotherapy group (P = 0.048). Excluding low grades, there was a trend for better LC with the use of postoperative chemotherapy (P = 0.06). There was a trend for worse LC in patients with a history of irradiation in the head 
discussion
For such rare tumors, randomized trials are hardly feasible and indeed require data collection over decades. This important homogeneous series focusing on this rare tumor of the young adult [11, [27] [28] thus has limitations including missing data for old patient charts and various chemotherapy protocols. It shows, however, a number of important directions. Consistent with published data, the current study showed a higher prevalence of Li Fraumeni syndromes or genetic disorders in children/adolescents [7, [29] [30] . Also, 14 cases were observed after radiotherapy, with median latency of 14 years after radiation therapy or chemotherapy [22, [31] [32] with 10-year latency [22, [33] [34] [35] [36] [37] and had worse prognosis, with 50% alive versus 80% of sporadic MOS [22, [33] [34] [35] [36] [37] [38] [39] [40] [41] . Fibroblastic cases were slightly more prevalent in the 14 irradiated patients. Swelling was a common mode of revelation [7, 11-12, 19, 22, 42] and numbness in the alveolodental nerve territory was of worse prognosis as half of them died. Misdiagnoses often led to delayed diagnosis [22, 26, [43] [44] . Although MRI better depicts soft-tissues and bone marrow infiltration (medulla) than CT scan, it was not systematically used for surgical planning of the resection margins. This may be one of the explanations for the rate of R1-R2 resection in this series. The role of these imaging modalities could not be assessed homogeneously owing to rapidly evolving imaging techniques over the period analyzed. A systematic histological review yielded a 5% rate of false diagnoses and provided detailed data on histological subtypes. The WHO 2002 grading system had the highest discriminating power. Here, the majority (91%) of cases was of conventional type (conventional NOS, chondroblastic, osteoblastic, and fibroblastic). Low-grade central or paraosteal type represented ≤5% of cases. The chondroblastic type appeared of better prognosis for survival as in several studies [2, 21, 45] and the fibroblastic type worse although the paucity of data prevents from establishing comparative rates. In this series, a number of conventional MOS were NOS and, overall, did worse than each other type separately, which is appealing for better characterization. Here, the median tumor size was 4.5 cm with five tumors measuring >8 cm [36] . The MSKCC staging system determined three clearly different prognostic groups whereas the Enneking's surgical staging system failed to do so.
The 5-year survival rate of the current series was 69%, similar to the published series of head and neck osteosarcomas [5, 13, 46] . The rate of metastases, none occurring in low-grade MOS, found here (29%) was slightly higher than the 17%-20% reported in the literature [10, 22, 47] . A local relapse occurred in almost half the patients and 61% of deaths were due to local failure versus 51% to metastases (15 patients having both local and metastatic failure) as in the literature [7, 10, 22-23, 25, 30, 48-50] .
MOS are characterized by a complex multidisciplinary management that must take into account the capacity of surgery to yield clear margins and perform a functionally efficient reconstruction as well as the risk of local relapse and metastasis [51] . The benefit of adjuvant treatment like radiation therapy on LC or chemotherapy on metastasis and survival must be discussed.The introduction of chemotherapy in the neoadjuvant setting [52] and/or adjuvant setting [53] in the management of high-grade osteosarcoma of the limbs increased DFS probabilities from only 10%-20% to >60% in the literature [54] . The favorable histological response rate according to Rosen's criteria in our series was 27% and did not influence DFS or survival directly but influenced the quality of margins. All nine intermediate-grade MOS and 69 of 74 highgrade MOS patients who had chemotherapy were alive at last follow-up. We showed a benefit of chemotherapy on DFS in high-grade MOS patients. Given the similar DFS profiles, intermediate-grade MOS may be considered as high-grade MOS and thus should be proposed neoadjuvant chemotherapy [55] . Kassir's head and neck MOS meta-analysis [6] [7] suggested that patients with positive margins and chemotherapy had worse survival rates than those with clear margins, but those with positive margins and no chemotherapy had the worst. Guadagnolo's study failed to demonstrate a benefit of chemotherapy in 56% of patients who underwent chemotherapy, over the 119 patients of the study [56] . Conversely, Smeele et al. [55] reported that survival and DFS were significantly improved with chemotherapy. In most studies, patients who received chemotherapy had poor prognostic factors including bulky tumor and marginal resection. Interestingly in our series, conventional, chondroblastic and osteoblastic subtypes had favorable response rates between 25% and 32%, consistent with the original articles Annals of Oncology published 25%-30% range [9, 57] , whereas none of the fibroblastic MOS patients undergoing chemotherapy had favorable histological response. The chondroblastic subtype has been found to respond better than the osteoblastic subtype [2, 22, 24] (unlike osteosarcomas of the limbs) and the fibroblastic worse. Most common protocols were API/AIbased, and methotrexate was sometimes added to adjuvant chemotherapy regimens. Interestingly, neoadjuvant high-dose methotrexate (mostly given in children) yielded the highest response rates (50%), but this did not translate into improvement of survival. The percent of necrosis as of Rosen's classification can be used to adapt adjuvant chemotherapy protocols but the ideal drug combination remains to be defined, although the most common seems to be doxorubicin and cisplatin-based in adults. For patients undergoing postoperative chemotherapy, those receiving API/AI protocols reached higher LC rates.
Radical surgery with wide clear margins is the principal prognosis factor for LC and survival [5, 10, 58] . Clear margins were also the main prognostic factor for LC and survival in the current series. The complete resection rate is 60%-70% for head and neck osteosarcomas, overall. Quite surprisingly, in this MOS series, the clear margin rate was 62.4% only. However, margins were not considered clear unless there was more than 0.5 cm of tumor-free tissue around the specimen [11] , when free-tissue measurements were reported in pathology reports (51%). Other studies used less stringent classification, such as 'clear margins' versus 'microscopic or macroscopic residual disease' [5] . Precise margins status all around the tumor should always be specified in pathology reports. It should include the measurement of tumor-free bone tissue along the axis of each end of the mandibular resection as well as the amount of soft tissue margins around the tumor. Nodal disease occurs in <5% of MOS and is associated with dismal prognosis independently of regional failure following neck dissection, thus suggesting not performing systematic neck dissection. The homolateral neck dissection rate in this series was indeed explained by the necessity of vascular access for free flap reconstruction.
In the current series, postoperative radiation therapy was carried out in 25 patients only, independently of margin status. The unexpectedly low prescription rate of irradiation here might be due to the notion that osteosarcomas are radioresistant, that irradiation of the oral cavity may be toxic and that in limb osteosarcomas, irradiation is not indicated. Given the limited number of cases, this study failed to demonstrate a clear benefit of irradiation, even for R1 disease. However, wide soft-tissue resection may be difficult in posterior localizations with potential involvement of masticatory muscles and infratemporal fossa. In Guadagnolo's series [56] as well as in Laskar's [3] , survival was significantly improved in R1-R2 patients with a median postoperative dose of 60 Gy. In this series including 41% head and neck osteosarcomas, Delaney noticed an improvement of LC in patients receiving >55 Gy [17] . Kassir et al. also recommended adjuvant radiation therapy in such situations [7] . According to these authors, the benefits on LC and survival exceed the risk of complications for patients with positive/uncertain margins [56] . Moreover, highly conformal innovative radiation techniques, such as intensity-modulated radiation therapy, may better preserve healthy tissues and reduce the rates of complications. On the whole, although it cannot be confirmed by the current series, there is level 2 evidence [3, 17, 56, 59] that radiation therapy, with doses of 60-66 Gy, should be of interest in case of close/positive margins when clear margins cannot be obtained surgically [60] . In locally advanced MOS with extensions into soft tissues such as the infratemporal fossa, large resection is hardly feasible. Such cases may be assumed as with incomplete margins and irradiation should be discussed on a case-by-case basis in multidisciplinary meetings. These preliminary data will be completed using our cohort through prospective collection of new cases, including ancillary studies, with the aim to improve diagnosis reliability and therapeutic management ( proposal in Figure 3 ), within the GSF-GETO [61] [62] .
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